To determine the pathophysiological role of S100A1 in endothelial cell (EC) function in experimental ischemic revascularization.
Integrative Physiology
C hronic critical limb ischemia (CLI), the most advanced form of peripheral arterial occlusive disease, is a common clinical problem with poor clinical prognosis. 1 Without successful revascularization, up to 40% of patients will require major limb amputation within 1 year of diagnosis, exceeding annual mortality rates of 20%. 1 Although we have seen rapid evolution of endovascular revascularization and improvement in medical treatment during the past 15 years, therapeutic options to improve bridge-collateral (arteriogenesis) and capillary formation (angiogenesis) are limited. 1 The prevailing lack of microvascular-targeted treatments fostered novel cell-and molecular-based strategies being tested in phase I and II clinical trials, with promising preliminary results. 2 In this regard, the most recent discovery of the EF-hand calcium (Ca 2+ ) binding protein S100A1 as virtually indispensable for postnatal endothelial cell (EC) function 3, 4 has sparked interest in its potential significance in vascular pathophysiology. Originally identified in the brain as a hydrophobic lowmolecular-weight (22 kDa) dimeric protein, S100A1 belongs to the largest subgroup of Ca 2+ sensors within the EF-hand Ca 2+ binding protein superfamily. 5 The group, referred to as S100 proteins, comprises 21 isoforms, each of which is characterized by a cell-specific and tissue type-specific expression pattern. S100A1, known for its high abundance in cardiomyocytes, controls a Ca 2+ -driven functional network orchestrating contractile performance, cell survival, and metabolism. 5 In ECs, S100A1 likewise seems to be an important part of the cell's versatile molecular tool kit to relay intracellular Ca 2+ oscillations that regulate vascular tone. 3, 4 Lack of endothelial S100A1 attenuates in vitro and in vivo arterial vasorelaxation basally and in response to B 2 -kininergic and M 2 -muscarinic stimuli. 3, 4 The Ca 2+ sensor interacts with the inositol-triphosphate receptor and enhances intracellular Ca 2+ release from the endoplasmic reticulum that indirectly accounts for enhanced endothelial nitric oxide synthase (eNOS) activation. 3, 4 However, it is unclear whether the EF-hand Ca 2+ sensor also might affect eNOS function directly. Hence, lack of S100A1 conveys endothelial dysfunction and suggests potential pathophysiological relevance in human vascular diseases.
In this study, we advance our understanding of the role of S100A1 in vascular disease biology and identify the Ca 2+ sensor as an indispensable factor for postnatal ischemic neovascularization with potential clinical relevance. First-time demonstration of a near-complete loss of S100A1 expression in ischemic tissue from patients with chronic CLI spurred a comprehensive proof-of-concept study in S100A1 genetically ablated (S100A1 knockout [SKO]) mice to determine its impact on postnatal ischemic neovascularization and underlying molecular mechanisms.
Methods
Detailed Methods are provided in the Online Supplement. For the assessment of hindlimb ischemia and protein-protein interactions, refer to the Online Supplement.
Patients
Briefly, in patients with chronic CLI and indication for surgical revascularization or major amputation, and in control patients, a surgical biopsy of the gastrocnemius muscle (GM) was performed. Patients gave their written informed consent to participate in the study. The study protocol has been approved by the ethics committee of the Medical Faculty at the Technische Universität Dresden.
Mice SKO mice were derived on a C57Bl/6 background, as described previously. 6 All experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee and complied with the Guide for the Care and Use of Laboratory Animals. For femoral artery resection (FAR), mice were anesthetized and the right femoral artery was resected as described. 7 In the course of the study, a modified minimal surgery was used. In some cases, wild-type (WT) and SKO mice were treated with the NO donor diethylenetriamine/NO (DETA/NO, 2 mg/kg) for 3 consecutive days immediately after FAR. 8
In Vivo Matrigel Plug Assay
Mice were anesthetized, 2 small subdermal pockets were created, and each pocket received 1 Matrigel plug. Plugs were harvested 16 days later. In some cases, mice received injections of DETA/NO (2 mg/kg) or vehicle (phosphate-buffered saline [PBS]). 8 Recovered plugs were cryoembedded, sliced, fixed, stained, and subsequently imaged (Image J).
RNA Isolation, Reverse Transcription, and Quantitative Real-Time Polymerase Chain Reaction
The procedures for RNA isolation, reverse transcription, and quantitative real-time polymerase chain reaction were essentially performed as described previously. 3
EC Preparation and Small Interfering RNA-Mediated Endothelial S100A1 Knockdown
Primary ECs from WT or SKO mice were prepared as described, 9 with modifications mentioned in the Online Supplement. Human microvascular ECs (HMVECs; CC-7030; Lonza) were cultured according to the manufacturer's instruction in EGM-2 MV BulletKit media (CC-3162). S100A1 knockdown (SKD) was achieved by transfecting cells with small interfering RNA against human S100A1 (Sigma 231-791-2) using the Lipofectamine RNAiMAX reagent (Invitrogen).
Skeletal Muscle Cell Isolation
GM bundles of male WT mice (2-3 months old) were dissected. 10 The isolated muscle bundles were treated with collagenase, and muscle cells were then incubated under normoxic and hypoxic (2% O 2 ) conditions.
[ 3 H]Thymidine Incorporation Assay
Agonist-induced [ 3 H]thymidine incorporation into ECs was assessed as described. 11
Chemokinesis Assay
EC migration was assessed according to a modified protocol from Liang et al. 12 ECs were seeded and allowed to attach overnight. After 24 hours of serum starvation (0.2% fetal bovine serum), the cell monolayer was denuded with a pipette tip and further incubated with 1% fetal bovine serum; ECs were then photographed to record a starting point. After 48 hours of incubation, cells were photographed again and closure of the denuded area was quantified.
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Immunoblot Analysis
Assessment of protein expression and phosphorylation from tissue and cellular extracts was performed as described in detail elsewhere; 3, 4 details can be found in the Online Supplement.
Measurement of Nitric Oxide and Nitrite in Cell Culture Supernatants and Tissue Homogenates
Nitric oxide (NO) in medium from EC cultures subjected to vascular endothelial growth factor (VEGF) stimulation or hypoxia was measured using an NO/nitrite/nitrate assay (R&D systems) according to the manufacturer's instructions. Nitrate levels in skeletal muscle tissue homogenates were measured with the nitrate/nitrite colorimetric assay kit (Cayman Chemicals 780001).
Measurement of NOS/eNOS Activity and PKC Activity
NO synthase activity from skeletal muscle tissue and ECs was mea sured with the NO synthase assay kit (Millipore) following the manu facturer's instructions. PKC activity from WT and SKO skeletal muscle tissue was measured with the PepTag protein kinase assay (Promega) following the manufacturer's instructions. PKC inhibitors were used as indicated.
Statistical Analysis
Student t test and 1-way ANOVA with Tukey posttest for multiple comparisons were used to analyze the appropriate data using GraphPad PRISM software. Fisher exact test was used to compare clinical score data by comparing mice with no evidence of hindlimb necrosis to mice with any evidence of necrosis. Data are presented as ±SEM in the Figures. P<0.05 was considered statistically significant.
Results

Loss of S100A1 Expression in Patients and Mice With CLI
Ischemic GM tissue biopsy samples from 5 patients with advanced chronic CLI (Rutherford stages 4-6) exhibited decreased S100A1 mRNA amounting to ≈5% of S100A1 levels in control biopsy samples ( Figure 1A ). Control nonischemic GM samples were derived from 3 patients with indication for elective knee arthroplasty and exclusion of peripheral arterial occlusive disease (for detailed patient characteristics see Online Table I ). Surgically induced hindlimb ischemia in C57BL/6 WT mice caused by right-side FAR mirrored the loss of S100A1 expression in ischemic GM tissue ( Figure 1B ). S100A1 expression levels in hypoxic ECs relevant to ischemic neovascularization were determined next. Murine arterial ECs exposed to 2% O 2 over 48 hours displayed rapid S100A1 mRNA downregulation ( Figure 1C ) similar to human iliac artery ECs (data not shown). S100A1 levels in isolated adult murine skeletal muscle fibers (Online Figure I ) involved in contractility regulation, however, exhibited lesser attenuation when treated with the same protocol ( Figure 1C ). Indicative of a greater susceptibility of ECs to hypoxia-induced loss of S100A1, our clinical observation prompted further investigation of the pathophysiological role of S100A1 in ECs in regenerative ischemic neovascularization, taking advantage of S100A1 gene-ablated mice (SKO).
High Rate of Autoamputation in SKO Mice With Experimental Hindlimb Ischemia
To determine the in vivo significance of our findings, we chose the model of experimentally induced CLI caused by Figure 1 . S100A1 is downregulated in critical limb ischemia (CLI). A, Digital subtraction angiography of a representative patient with peripheral arterial occlusive disease (PAOD) caused by femoropopliteal arterial obstruction (arrow points to site of proximal arterial obstruction). Gastrocnemius muscle biopsy samples (arrowhead) were analyzed for S100A1 mRNA expression using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) (n=3 control, 5 CLI; *P<0.05; scale bar, 5 cm). B, Wild-type (WT) mice were subjected to femoral artery resection (FAR), and S100A1 protein levels in gastrocnemius muscle samples were assessed by immunoblot analysis before (nonischemic [NI]) or 3 days after FAR (ischemic [I]) (n=3 each; *P<0.05 vs NI). C, Isolated primary murine WT endothelial cells (ECs) or skeletal muscle fibers were subjected to hypoxia for up to 2 days. mRNA was extracted and subjected to qRT-PCR for S100A1 (n=3; *P<0.05 vs EC).
FAR in 8-to 12-week-old WT and SKO mice. Recovery from hindlimb ischemia was classified using a clinical score as previously described (Online Methods). 13 In WT mice, active use of the right foot declined after surgery but improved by day 7, and activity of the preserved limb ultimately returned to nearnormal levels, with an average score <1 by day 15 (Figure 2A) . A similar abrupt but persistent reduction in hindlimb use occurred in SKO mice that developed into partial or total autoamputation of the affected limb (average score >3) in 80% of SKO mice between 7 and 14 days after FAR (Figure 2A ). Suggestive of a lack of regenerative reperfusion and revascularization, we next measured arterial blood flow recovery in ischemic SKO hind limbs after FAR.
Impaired Reperfusion and Neovascularization in Ischemic Hind Limbs of SKO Mice
Arterial limb perfusion recovery was examined by pulsed-wave Doppler ultrasonography (Online Figure II ). 14 SKO mice at risk for autoamputation never achieved more than 25% to 35% perfusion in the tibialis posterior artery of ischemic hind limbs 1 and 2 weeks after FAR ( Figure 2B ). Accordingly, direct measure of ischemic tissue perfusion using colored microspheres at day 15 after FAR unveiled an 80% blood flow reduction in SKO ischemic limbs compared with controls ( Figure 2C ). Structural analysis of postischemic bridge-collateral formation by immunofluorescent smooth muscle actin staining and infraabdominal aortic corrosion cast, respectively, revealed no evidence for decreased arteriogenesis in SKO animals compared with WT-FAR ( Figure 3A ; Online Figure III ). However, histological and immunofluorescent analyses of the EC marker von Willebrand factor and CD31, respectively, yielded a significant reduction of the capillary/fiber ratio in ischemic SKO muscle tissue ( Figure  3B ). Indicative of a predominant defect in postischemic angiogenesis, we raised the question of whether loss of S100A1 per se might compromise proangiogenic properties of ECs.
Blunted Proangiogenic Properties of SKO ECs and Rescue of Defective Capillary Formation by NO
Isolated SKO ECs displayed significantly lower proliferation ( Figure 4A ) and migration rates ( Figure 4B ) than WT ECs under normoxic conditions. Similarly, formation of capillary-like tube networks on growth factor-supplemented Matrigel was compromised in SKO ECs ( Figure 4C ). We next determined whether these defects might translate into distorted angiogenesis in vivo. To this end, we used subcutaneously implanted Matrigel plugs in 12-week-old WT and SKO mice that were harvested 16 days later. Bases of Matrigel plugs explanted from WT mice were densely populated by CD31-positive ECs, and smooth muscle actin-stabilized capillaries were traceable up to the plug's center sections ( Figure 4D ). In contrast, Matrigel plugs recovered from SKO mice unveiled a significantly lower number of organized capillaries at the bottom and fewer penetrations toward the center ( Figure 4D ). Importantly, intraperitoneal NO supplementation with DETA/NO was sufficient to rescue this defect. A DETA/NO dosage was used, which was previously described not to significantly change blood pressure or heart rate in mice (2 mg/kg) but to exert NO-dependent cardiac protection. 8 Explanted Matrigel plugs 16 days after DETA/NO treatment displayed marked improvement of capillary neoformation that was virtually indistinguishable from WT mice ( Figure 4E ). The NO-mediated rescue directed our attention to molecular abnormalities in S100A1-deficient ECs that contribute to distorted postischemic NO and capillary formation.
Abrogated NO Generation in Ischemic Hind limbs of SKOs and Abnormal eNOS Regulation in S100A1-Depleted ECs
SKO ischemic GM tissue samples showed blunted postischemic NO production compared with WT-FAR mice ( Figure 5A ). Abnormalities in VEGF-and hypoxia-mediated eNOS function in SKO ECs are unknown. Here, we demonstrate for the first time an attenuated NO generation in response to VEGF and hypoxia in cultured SKO ECs compared with WT ECs ( Figure 5B and Online Figure IVB, respectively). To elaborate on potential mechanisms, HMVECs were subjected to small interfering RNA-mediated knockdown of S100A1 (HMVEC-SKD), which resulted in ≈80% reduction of the protein after 48 hours (Online Figure IVA) . Like SKO-derived ECs, HMVEC-SKDs responded with abrogated NO generation to stimulation by VEGF or hypoxia (2% O 2 ; Figure 5C and Online Figure  IVC , respectively). Subsequent phosphorylation analysis of the inhibitory eNOS threonine 495 (p-T495) site revealed significantly augmented levels in HMVECs-SKDs, whereas control HMVECs demonstrated enhanced phosphorylation of the stimulatory serine 1177 (p-S1177) site ( Figure 5D ). The previously demonstrated ability of S100 proteins to attenuate protein kinase C (PKC) activity, which plays a critical role in p-T495 phosphorylation, 15 prompted us to study PKC activity. 16, 17 In line with abnormal eNOS regulation, HMVEC-SKDs exhibited significantly greater PKC activity under VEGF stimulation than control cells ( Figure 5E ). Inhibition of PKC with the chemical compound calphostin-C prevented the increase in eNOS pT-495 (Online Figure VA) . Consequently, HMVEC-SKDs experienced a significantly greater relative increase in Figure 3 . Impaired reperfusion and neovascularization in ischemic hind limbs of S100A1 knockout (SKO) mice. A, Wild-type (WT) and SKO mice were subjected to femoral artery resection (FAR) and procured at times indicated. The arterial hindlimb circulation was corrosion-casted to visualize developing collaterals (n=4 for each genotype; scale bar, 10 mm). B, SKO and WT mice were subjected to FAR, and gastrocnemius muscles from ischemic and contralateral nonischemic limbs were procured 15 days later. Paraffin-embedded cross-sections were immunohistochemically stained for von Willebrand factor (vWF; arrows, counterstained with hematoxylin and eosin to visualize nuclei and fibers, respectively) or immunofluorescently stained for CD31 (CD31, green; nuclear DNA was visualized with Hoechst 33342, blue). Note decrease in CD31 staining in ischemic SKO muscle tissue. Representative cross-sections are shown (scale bar, 200 μm). Fibers and capillaries positive for vWF were counted in the paraffin-embedded cross-sections, and the resulting ratio was graphed (n=5 for each genotype; *P<0.05 vs ischemic SKO). Figure VB) . The partial restoration of NO generation by PKC inhibition suggested an additional mechanism and spurred the question of whether S100A1 might directly interact and modulate eNOS activity in ECs and ischemic tissue.
NO generation on PKC inhibition than control cells (Online
S100A1 Directly Interacts With eNOS in ECs in a Ca 2+ -Dependent Manner
In support of this argument, S100A1 coprecipitated with eNOS in a Ca 2+ -dependent manner using murine EC lysates ( Figure 6A ). Abrogated eNOS/S100A1 interaction by EGTA corroborated Ca 2+ dependency of their binding. Increasing cytosolic Ca 2+ concentrations in these cells using either bradykinin or the Ca 2+ ionophore A23187 before extract preparation and immunoprecipitation further enhanced S100A1-eNOS interaction ( Figure 6A ). Addition of increasing concentrations of recombinant human S100A1 protein (rhS100A1) to homogenates of human umbilical vein ECs showed dose-dependency of the Ca 2+ -dependent binding between both human proteins, and similar results were obtained with adenovirally overexpressed S100A1 in human umbilical vein ECs (data not shown). Brief hypoxia (2% O 2 for 2 hours), which does not appreciably result in loss of S100A1 protein, similarly augmented S100A1/eNOS binding in control HMVECs (Online Figure VI) . When examined by confocal microscopy both in murine WT ECs and in human iliac artery ECs, S100A1 displayed a granular cytosolic pattern and colocalized with eNOS throughout the cell ( Figure 6B ). Using the in situ Duolink assay, the distinct S100A1/eNOS interaction pattern could be confirmed in intact human umbilical vein ECs that corroborated the immunoprecipitation studies ( Figure 6B ).
S100A1 Protein Positively Modulates Activity of eNOS
To determine whether this interaction actually modulates function of the enzyme, we performed reconstituted eNOS activity assays using both recombinant bovine eNOS and immunoprecipitated eNOS from EC lysates. As shown in Figure 6C , addition of increasing concentrations of rhS100A1 dose-dependently augmented the Ca 2+ /calmodulin (CaM)-dependent arginine-citrulline conversion rate of bovine recombinant and EC-derived eNOS. Interestingly, quantitative assessment of the CaM-eNOS interaction in S100A1-overexpressing and control human umbilical vein ECs applying the Duolink assay provided no evidence for enhanced CaM-eNOS binding through increased cellular S100A1 protein levels (Online Figure VII) . Vice versa, increasing concentrations of recombinant CaM did not attenuate S100A1 coprecipitating with eNOS (data not shown). These results indicate an additive activation of eNOS through both Ca 2+ sensors rather than mutually competitive or facilitated binding. Incubation of immunoprecipitated eNOS from both groups with recombinant CaM resulted in a significantly greater increase in eNOS activity from S100A1competent WT tissue than SKO. Ensuing administration of rhS100A1 protein further increased eNOS activity from SKO, corroborating the additive effect of both Ca 2+ sensors ( Figure 6D ). Indicating that S100A1 deficiency both directly Figure 5 . Reduced vascular endothelial growth factor (VEGF)-stimulated Nitric oxide (NO) production in S100A1 knockout (SKO) endothelial cells (ECs) and hindlimbs. A, NO synthase (NOS) activity of skeletal muscle extracts procured at different times after femoral artery resection was assessed by measuring nitrite production (n=6; *P<0.05 SKO vs wild-type [WT]). B, Primary ECs derived from WT and SKO mice or (C) human microvascular ECs (HMVECs) subjected to small interfering RNA (siRNA)-mediated knockdown of S100A1 were treated with 50 ng/mL VEGF for 16 hours. Endothelial NOS (eNOS)-derived nitrite was determined in the cell supernatant as described in the Methods section (*P<0.05 vs untreated WT or VEGF-treated SKO [B] or S100A1 siRNA [C], respectively; experiments were performed in duplicate and repeated 3 times). D, VEGF-dependent phosphorylation status of p-S1177 or p-T495 eNOS was examined in HMVECs subjected to S100A1 knockdown (*P<0.05 vs S100A1 kd pT495 eNOS; #P<0.05 vs scr pS1177 eNOS). E, Protein kinase C (PKC) activity was examined in HMVECs subjected to S100A1 knockdown and treated with 50 ng/mL VEGF for 15 minutes. (n=3 independent assays, performed in triplicate). Calphostin-C (100 ng/mL) was included to inhibit PKC, where indicated. and indirectly impairs eNOS function, we continued to investigate how these molecular abnormalities might affect in vivo responsiveness and efficiency of the VEGFphosphoinositide-3-kinase (PI3K)-Akt-eNOS signaling axis in ischemic tissue.
Excessive Postischemic VEGF Levels and Attenuated VEGFR2 Signal Relay in SKO Ischemic Hindlimbs
Analysis of the oxygen sensor hypoxia-inducible factor 1α, which is known to drive VEGF expression, 18 revealed significantly greater protein levels in ischemic SKO than ischemic WT GM ( Figure 7A ). Concordantly, postischemic abundance of VEGF protein in SKO hindlimbs exceeded the VEGF increase in WT tissue by ≈10-fold ( Figure 7B ). Similar abnormalities were found for other hypoxia-regulated growth factors, including hepatocyte growth factor, placental growth factor, and insulin-like growth factor (Online Figure  VIII) , indicating unresolved ischemia in SKO hind limbs. Previous studies that reported rapid degradation of VEGF receptor-2 (VEGFR2) in response to sustained VEGF stimulation via a PKC-dependent mechanism 19,20 prompted investigation of abundance and phosphorylation status of key effectors along the VEGFR2 signaling axis. Both total and phosphorylated VEGFR2 protein levels were barely detectable in ischemic SKO tissue extracts compared with only a slight decrease in ischemic WT ( Figure 7C ). When HMVEC-SKDs were exposed to VEGF, faster in vitro VEGF2 degradation was observed compared with controls, and this effect was blocked by the PKC inhibitor calphostin-C (Online Figure IX) . Interestingly, ischemic SKO tissue unveiled significantly higher postischemic PKC activity (Online Figure X) , akin to enhanced PKC activity in hypoxic HMVEC-SKDs. Accordingly, relative active phosphorylation status of VEGFR2 downstream effectors, such as PI3Kγ, phosphoinositide-dependent protein kinase, and Akt, was significantly lower in ischemic SKO-derived GM compared with ischemic WT, whereas total levels were significantly higher ( Figure 7D , Online Figure XIA ). VEGFR1 in vivo levels were unchanged in both groups ( Figure 7C ), whereas the downstream activity of the phospholipase-C-γ-ERK1/2 axis was significantly higher in ischemic SKO than WT tissue (Online Figure XIB) . In line with published reports, 19 we confirmed that VEGR1 remains unaltered in ECs in response to prolonged VEGF stimulation (Online Figure XII) . Besides evidence for blunted postischemic VEGFR2 signaling in SKO, the postischemic VEGF overshoot also might entail dysbalanced VEGFR1 activity.
Inhibitory eNOS Phosphorylation Pattern in SKO Ischemic Hind Limbs
Driven by abnormal in vitro eNOS regulation and attenuated in vivo VEGFR2-PI3K-Akt signaling, 21 we next raised the question of whether eNOS phosphorylation pattern and Figure 6 . S100A1 interacts with endothelial nitric oxide (NO) synthase (eNOS) and regulates its activity. A, Lysates were prepared from endothelial cells (ECs) pretreated, or not, with A23187 or bradykinin. In a separate experiment, immunoprecipitations were performed in the presence of Ca 2+ or EGTA. Immunoblots were probed for the presence of eNOS or S100A1. Representative blots are shown, and the experiment was repeated at least 3 times with similar results. B, ECs were immunofluorescently labeled with an antibody to eNOS (red) or S100A1 (green) and assayed by confocal microscopy (magnification ×40; scale bar, 40 μm); enlarged merged images show partial colocalization (yellow). Close protein contact between S100A1 and eNOS was also shown using the Duolink assay (magnification ×60; scale bar, 10 μm). C, Recombinant bovine eNOS (top) or eNOS immunoprecipitated from human umbilical vein EC (HUVEC) extract (bottom) was incubated with 1 mmol/L Ca 2+ in the presence or absence of calmodulin (CaM) and increasing amounts of rhS100A1, as indicated. eNOS activity was determined by measuring the conversion of [ 3 H] l-arginine to l-citrulline. #P<0.05 vs reaction in the absence of added S100A1. *P<0.05 vs reaction in the absence of added CaM and rhS100A1. The experiment was performed in duplicate and repeated 3 times. D, Wild-type (WT) and S100A1 knockout (SKO) mice were subjected to femoral artery resection, and extracts from ischemic muscles were prepared 3 days later and used to immunoprecipitate eNOS. eNOS activity in the immunoprecipitates was assayed with or without added CaM and S100A1 and adjusted to eNOS protein content (n=6; *P<0.05 SKO vs WT).
expression were similarly modified in ischemic tissue from SKO mice. Interestingly, ischemic SKO GM tissue unveiled ≈2-fold increase in total eNOS protein expression over WT ( Figure 8A ). In line with our in vitro results, the enzyme exhibited >7-fold increase in phosphorylation of the inhibitory phospho-threonine 495 (p-T495) over the stimulatory phospho-serine 1177 (p-S1177) site ( Figure 8A ) compared with WT. Among PKC isoforms that are known to attenuate Ca 2+ /CaM-dependent eNOS activity through p-T495 phosphorylation, 15 expression analysis showed a marked increase in PKC-ε protein and phosphorylation levels ( Figure 8B ) in accordance with elevated PKC activity in ischemic SKO tissue homogenates (Online Figure X) . Expression analysis of PP1, which dephosphorylates the p-T495 site, 15 showed no difference between groups (data not shown).
Direct NO Substitution Salvages Ischemic Limb Loss in SKO Mice
Given the fact that NO administration is sufficient to rescue defective in vivo angiogenesis in SKOs, we finally sought to answer the question whether the observed lack of NO bioavailability is actually causative for tissue necrosis in SKO FAR mice. To this end, WT and SKO animals were treated with DETA/NO for 3 consecutive days immediately after FAR. Using the same dosage that rescued in vivo angiogenesis in SKO mice, NO treatment completely prevented autoamputation in all SKO mice (clinical score <1), whereas 5 of 6 saline-injected SKO mice still displayed evidence of limb necrosis 15 days after FAR ( Figure 8C ). Our in vivo rescue corroborates defective NO bioavailability as key for the postischemic SKO phenotype and NO supplementation as Figure 7 . Augmented activation of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) in the ischemic hind limb of S100A1 knockout (SKO) mice disturbs VEGF receptor 2 (VEGFR2) signaling. SKO and wild-type (WT) mice were subjected to femoral artery resection, and gastrocnemius muscles of the ischemic and contralateral nonischemic hindlimb were procured and homogenized after 3 days (except for VEGF). Representative samples are shown for all immunoblots. Muscle extracts were immunoblotted for (A) HIF-1α, (B) VEGF (at times indicated), (C) total and p-Y1175 VEGFR2 and VEGFR1, and (D) total and p-S473-Akt. All expression levels were normalized to GAPDH (n=4 for each genotype and condition; *P<0.05 vs ischemic WT).
sufficient to bypass abnormal eNOS regulation and restore defective angiogenic activity.
Discussion
This is the first report providing direct genetic evidence for a critical role of S100A1 in postnatal ischemic angiogenesis.
Most salient findings of this study, which originate from the clinical finding of diminished S100A1 expression in patients with CLI, are the identification of endothelial S100A1 as an indispensable factor for mounting an adaptive angiogenic response to ischemia, and as a stimulatory eNOS-interacting protein critical for postischemic NO generation. To determine the role of S100A1 in postischemic revascularization and to decipher underlying cellular and molecular mechanisms, we took advantage of the hindlimb ischemia model in SKO mice. Among the relevant differentiated cell types expressing S100A1 in muscle tissue, ECs emerged as particularly susceptible to a hypoxia-induced loss of S100A1 expression. Hence, our focus was drawn to the impact of S100A1 on in vitro and in vivo endothelial proangiogenic properties that are essential for reparative neovascularization.
After surgical blood flow interruption, 7,13 SKO mice exhibited a high rate of tissue necrosis and subsequent autoamputation of ischemic limbs because of insufficient NO generation. Similarly, severe phenotypes have been observed in mice with homozygous ablation of Akt1 and eNOS, 7,13 which groups S100A1 alongside genes that are crucial for postnatal neovascularization through the modulation of NO homeostasis. In support of this notion, assessment of changes in postischemic blood flow revealed failure of arterial perfusion recovery in SKO mice akin to Akt1 −/− and eNOS −/− mice undergoing FAR. 7, 13 However, ensuing investigation of bridge-collateral formation that fuels distal blood flow and occurs under normoxic conditions 22 even showed a trend toward augmented collateral wall formation in SKO. This implicates at least normal smooth muscle cell expansion compared with WT and is consistent with reports on unchanged function of S100A1deficient smooth muscle cells. 3, 4 But, as shown previously, S100A1-deficient endothelium blunted normoxic arterial NO generation and dilation in response to endogenous vasorelaxing factors. 3, 4 It is thus conceivable that normal amounts of collateral arteries grew in SKOs after FAR but were unable to dilate adequately because of dysfunctional S100A1deficient endothelium. 22 The endothelial defect could explain, in part, diminished arterial blood flow recovery in SKO mice. Notwithstanding, evaluation of exercise-based and shearstress-based vasodilation of SKO arteries is needed to fully understand the role of S100A1 in EC-dependent arterial reserve mechanisms. 22 Turning our attention to angiogenesis then unveiled a striking difference in postischemic microvasculature formation that clearly distinguished FAR SKO from WT mice. Ischemic limbs of WT mice exhibited the expected hypoxia-driven enhancement of capillary formation. 13 In contrast, SKO mice failed to mount an adaptive angiogenic response. Hence, SKO that experienced autoamputation may not have even reached the critical threshold of newly formed microvasculature necessary to preserve their limbs. In line with this argument, essential steps of the fine-tuned sequence of postischemic capillary formation, including EC proliferation, migration, and capillary-like tube network formation, 23, 24 were all severely compromised in SKO ECs. Use of an integrative in vivo angiogenesis assay 24 substantiated the postnatal inability of SKO mice to create 3-dimensional capillary networks. Although these assays are not representative of the site and environment where postischemic angiogenesis occurs, 24 they nevertheless unearth a basic defect in SKO ECs that might explain, in part, defective postischemic angiogenesis seen in Figure 8 . A, Muscle extracts from wild-type (WT) and S100A1 deficient (SKO) mice were prepared 3 days after femoral artery resection (FAR) and immunoblotted for endothelial NO synthase (eNOS; total, p-T495 and p-S1177) and (B) total and p-protein kinase C (PKC)-ε. C, SKO mice underwent FAR and received the NO donor diethylenetriamine/NO (DETA/ NO; 2 mg/kg, IP) or saline daily for the following 3 days. Clinical score was assessed at day 15 postoperatively (n=6; *P<0.05 vs nonischemic saline, *P<0.05 vs SKO+DETA/NO).
vivo. These results further imply a pathophysiological role of the hypoxia-driven loss of endothelial S100A1 expression for impaired revascularization seen in patients with chronic CLI. Molecular mechanisms attenuating S100A1 expression in hypoxic ECs remain to be determined.
Despite the complexity of postischemic capillary neoformation, NO emerged as an ultimate signaling molecule governing this process. 25 In line with this notion, we found impaired NO generation both in S100A1-deficient ischemic tissue and in hypoxic and VEGF-stimulated S100A1-depleted ECs. Previous reports already have attributed abnormal Ca 2+ mobilization from intracellular stores in SKO ECs to diminished Ca 2+ -dependent NO generation in response to B 2 -kininergic and M 2 -muscarinic stimuli. 3, 4 Although VEGFmediated eNOS activation relies in part on Ca 2+ mobilization, 25 the severity of the SKO phenotype suggested an even more substantial role of S100A1 in postischemic eNOS regulation. Ensuing molecular and imaging studies actually revealed first evidence for a direct Ca 2+ -dependent stimulatory interaction of S100A1 with eNOS in ECs. S100A1 protein dosedependently augmented eNOS activity and potentiated the effect of Ca 2+ /CaM-dependent stimulation without evidence for facilitated CaM-eNOS interaction in ECs. These novel results support the notion that S100A1 might be a direct and positive modulator of eNOS function and advance our current understanding of the molecular actions of S100A1 in ECs. These data provide the rationale for continued studies determining the relevant binding domains between eNOS and S100A1 and its impact on other accessory eNOS modulators, such as Hsp90 or caveolin-1, in greater detail. 15 In addition, our study unveiled another novel regulatory mechanism by which S100A1 can indirectly modulate eNOS function that involved PKC. S100 proteins have been reported to attenuate PKC activity by interfering directly with PKC or indirectly with PKC substrates. 16, 17 The kinase previously has been described to negatively interfere with eNOS activity by p-T495 phosphorylation. 15 Here, we first demonstrate that S100A1 is necessary to attenuate PKC-dependent inhibitory phosphorylation of eNOS in VEGF-stimulated ECs. Partial restoration of NO generation in S100A1-depleted ECs by chemical PKC inhibition corroborates the significance of this finding. Because it is still not entirely clear how S100 proteins can mitigate PKC activity, more work is required to uncover the mechanism that confers S100A1-mediated inhibition of PKC in ECs. Nonetheless, from the deepened mechanistic insight, we conclude that compromised postischemic eNOS function in SKO and S100A1-depleted ECs is most likely orchestrated both by interrupted stimulatory S100A1/eNOS interaction and by augmented p-T495 eNOS phosphorylation caused by PKC hyperactivation.
Both molecular defects seem to have the potential to negatively amplify each other and might essentially contribute to blunted in vivo proangiogenic properties of S100A1-deficient ECs. Therefore, we next focused on in vivo consequences by examining the VEGF signaling axis and eNOS posttranslational modifications. Reflecting unresolved tissue ischemia, 18 protein levels of the main oxygen sensor hypoxia-inducible factor 1α were significantly higher in ischemic SKO tissue, and ensuing VEGF accumulation in operated SKO limbs exceeded the ischemic response in WT mice by >10-fold. But excessive VEGF production is not a genuine defect of SKO ECs because in vitro hypoxic VEGF production was indistinguishable from WT ECs (data not shown). Interestingly, eNOS −/− mice subjected to FAR responded with a postischemic decrease in VEGF mRNA expression because of a proposed concurrent genetic defect, 26 indicating that the SKO phenotype might differ substantially with respect to adaptive proangiogenic pathways. The concomitant increase of the angiogenically active cytokines hepatocyte growth factor, insulin-like growth factor, and placental growth factor in SKO after FAR further substantiates the view of a rather futile secondary VEGF overshoot that might, in turn, disturb the finely regulated proangiogenic cross-talk between growth factors. 19 This is important to note because sustained VEGF stimulation can result in rapid downregulation and degradation of its receptor tyrosine kinase VEGFR2. 19 In contrast to WT, assessment of VEGFR2 protein and phosphorylation uncovered virtually undetectable levels in ischemic SKO tissue. A potentially causal role for endothelial S100A1 herein emerged from our in vitro results showing accelerated VEGFR2 degradation in VEGF-stimulated S100A1-depleted ECs. Attenuation of this defect by a chemical PKC inhibitor once more implies a role for PKC, which is involved in VEGFmediated VEGFR2 downregulation and degradation. 19, 20 Enhanced PKC activity in S100A1-depleted ECs therefore might contribute to in vivo VEGFR2 degradation in SKO mice. In line with prevailing literature, 19, 27 it is tempting to speculate that loss of S100A1 feeds into a vicious cycle of reduced in vivo VEGF responsiveness nurtured in part by endothelial VEGFR2 degradation, which again fuels a secondary VEGF overshoot and compromises residual angiogenic capacity in SKOs. Accordingly, the downstream PI3K-Akt-eNOS signaling cascade, which accounts for many of the VEGF actions, including EC proliferation, migration, tube formation, and promotion of the release of NO, 23 yielded marked abnormalities in ischemic SKO tissue. Relative active site phosphorylation levels for phosphoinositide-dependent protein kinase and Akt were reduced, supporting the notion of abrogated activation. In this regard, permanent upregulation of PI3K, phosphoinositide-dependent protein kinase, Akt, and eNOS protein expression might be viewed as compensatory attempts to uphold efficacy. Interestingly, eNOS −/− mice subjected to FAR displayed similarly decreased postischemic Akt activation, although opposed to SKOs, total Akt levels were reported to be unchanged. 28 Most importantly, however, the balance between activating and inhibitory phosphorylation of eNOS in ischemic SKO samples was significantly shifted in favor of the p-T495 site. This observation is consistent with diminished in vivo ischemic NO bioavailability and mirrors our in vitro results of an abnormal eNOS phosphorylation pattern in S100A1depleted ECs on VEGF stimulation. 15, 21, 25 In view of our in vitro data, enhanced in vivo activity of PKC in ischemic SKO tissue also might be partly accountable for inhibitory eNOS phosphorylation. In support of this notion, indistinguishable expression and phosphorylation of PP1 between groups rather exclude a role for abnormal activity of the phosphatase assigned to the p-T495 site. 15 The role of other phosphatases potentially regulated by S100A1, such as protein phosphatase 5, 29 however, requires further evaluation. Increased PLCγ expression and ERK1/2 activity might finally result from a relative increase in VEGFR1 signaling 19 because of imbalances between VEGFR2 and VEGFR1 levels in ischemic SKO tissue. This might add to signaling abnormalities in ischemic SKO tissue.
Ultimate proof for the pathophysiological key role of compromised eNOS function in the SKO phenotype came from rescue experiments using pharmacological NO supplementation. NO was sufficient both to salvage ischemic SKO limbs and to restore in vivo microvasculature formation. Interestingly, a previous study showed that DETA/NO did not improve angiogenesis in ischemic hindlimbs of eNOS −/− mice. 13 But this study used a 25-fold higher DETA/NO concentration, which suppressed in vivo angiogenesis in WT mice (data not shown). Hence, it seems reasonable to assume that endothelial S100A1 deficiency might blunt in vivo ischemic NO generation and angiogenesis through interrupted S100A1-facilitated eNOS activation, unopposed PKC-mediated p-T495 phosphorylation, and VEGFR2 degradation.
Despite the potential relevance of these novel mechanistic findings, important limitations of our study are noteworthy. First, FAR-induced hindlimb ischemia in otherwise healthy mice is not equivalent to CLI in humans, which is frequently associated with comorbid illnesses 30 and thereby warrants evaluation of the role of S100A1 in the context of hyperglycemia and hypercholesterolemia. Second, in light of previously reported functions of S100A1 in endothelial Ca 2+ homeostasis, 3, 4 we expect dysfunctional eNOS not to be the sole mediator of the postischemic SKO phenotype. 23 Besides NO, Akt suppresses various proapoptotic pathways, and given attenuated Akt activity, extended analysis of the potential susceptibility of SKO ECs to cell death is certainly needed. Third, oxidative stress resulting from inflammation and potential eNOS uncoupling also may play a role in defective angiogenesis in SKO mice. 25 Fourth, NO generation in cellular assays was measured only indirectly by assessing NO 2 − /NO 3 − levels. More sensitive assays are certainly needed in subsequent studies deciphering the impact of the S100A1/ eNOS interaction on NO homeostasis. Finally, a contribution of altered S100A1 skeletal muscle expression to ischemic limb loss is possible. The observed marginal attenuation of S100A1 expression in differentiated hypoxic skeletal muscle fibers and barely de tectable S100A1 expression in WT skeletal myoblasts (Online Figure XIII) nevertheless weaken the notion of a relevant role of skeletal muscle S100A1, at least in angiogenesis.
Overall, our clinically driven experimental study identifies S100A1 as critical for postnatal ischemic angiogenesis and eNOS function. Our molecular results, summarized in Online Figure XIV , provide advanced mechanistic insight demonstrating that the lack of endothelial S100A1 might attenuate in vivo eNOS activity by at least 3 distinct but additive/synergistic pathomechanisms: interrupted stimulatory S100A1/ eNOS interaction; PKC hyperactivity that triggers inhibitory eNOS phosphorylation and abrogates VEGFR2 signal relay; and, as previously shown, 3 insufficient inositol-triphosphate receptor-mediated Ca 2+ release required for eNOS activation.
These findings will prompt further studies to probe the microvascular therapeutic potential of restoring S100A1 levels in ischemic vascular disease.
